Search alternatives:
point decrease » point increase (Expand Search)
non decrease » note decreased (Expand Search), fold decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
non decrease » note decreased (Expand Search), fold decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
16641
-
16642
Table 5_Interaction with IGF1 overrides ANXA2-mediated anti-inflammatory functions of IGFBP5 in vivo.docx
Published 2025“…Background<p>IGFBP5 is a differentially expressed gene (DEG) between M1 and M2 macrophages. …”
-
16643
Image_5_Autophagy Induced Accumulation of Lipids in pgrl1 and pgr5 of Chlamydomonas reinhardtii Under High Light.TIF
Published 2022“…<p>Chlamydomonas (C.) reinhardtii is a potential microalga for lipid production. Autophagy-triggered lipid metabolism in microalgae has not being studied so far from a mutant of proton gradient regulation 1 like (PGRL1) and proton gradient regulation 5 (PGR5). …”
-
16644
BMD analysis of serum free T4 (A), serum free T3 (B) and serum TSH (C) in males (triangles) and females (circles).
Published 2014“…Small symbols indicate individual samples, large symbols the group mean; the vertical dotted line indicates the dose (CED) with 5% decrease or increase (CES -0.05) compared to background (a parameter). …”
-
16645
Table_1_Investigating the Added Value of the EQ-5D-5L With Two Bolt-On Items in Patients With Hemophilia.DOCX
Published 2021“…Spearman's rank correlation (rho) was used to assess the associations of the EQ-5D-5L and two bolt-on items with the Hemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL) and SF-12. …”
-
16646
-
16647
Comparison of the outcome of non-Markovian SIR processes for different values of the parameter <i>ϵ</i>.
Published 2015“…</mo><mn>2</mn></mrow></msubsup></mrow></math>; nodes’ recovery times followed <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1004579#pcbi.1004579.e103" target="_blank">Eq (23)</a> with <i>γ</i> = 1.5 and <i>μ</i><sub>0</sub> = 10<sup>−4</sup> Hz; the length of a time-step was Δ<i>t</i> = 1 s and the infection rate β = 100μ<sub>0</sub> = 10<sup>−2</sup> Hz.…”
-
16648
Design of a RSSCA system for agriculture.
Published 2025“…<div><p>Agricultural land is increasingly under pressure from expanding solar energy infrastructure, leading to a growing conflict between food and energy production. …”
-
16649
-
16650
Ybx1 regulation of its target mRNAs is m<sup>5</sup>C-depdendent (Related to Fig 5).
Published 2025“…<p><b>(A)</b> RT-qPCR confirmed the decreased expression levels of Ybx1 target mRNAs in neural stem cells with Ybx1 knockdown using siRNA. …”
-
16651
Image_2_Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment.TIF
Published 2021“…As a stable indicator, the changes in IL-6 levels could indicate the inflammatory conditions during a viral infection. …”
-
16652
Image_6_Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment.TIF
Published 2021“…As a stable indicator, the changes in IL-6 levels could indicate the inflammatory conditions during a viral infection. …”
-
16653
Image_1_Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment.TIF
Published 2021“…As a stable indicator, the changes in IL-6 levels could indicate the inflammatory conditions during a viral infection. …”
-
16654
Image_3_Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment.TIF
Published 2021“…As a stable indicator, the changes in IL-6 levels could indicate the inflammatory conditions during a viral infection. …”
-
16655
Image_4_Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment.TIFF
Published 2021“…As a stable indicator, the changes in IL-6 levels could indicate the inflammatory conditions during a viral infection. …”
-
16656
Five years comparation of efficacy and safety after ICL-V4c implantation for high and super high myopia correction
Published 2024“…No significant difference of ECD was found in the high (2823.45 ± 274.75 cells/mm<sup>2</sup>) and super-high myopia (2856.71 ± 323.53cells/mm<sup>2</sup>) at the visit of 5 years. Compared to baseline, we observed a significant increase in IOP at the 1-week follow-up, which decreased significantly at the one-month visit. …”
-
16657
List of Included studies.
Published 2025“…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
-
16658
The search strategy in three databases.
Published 2025“…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
-
16659
NIH score.
Published 2025“…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
-
16660
List of excluded studies.
Published 2025“…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”